Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis

2021 ◽  
Author(s):  
James M. Halle-Smith ◽  
Lewis Hall ◽  
Lois A. Daamen ◽  
James Hodson ◽  
Rupaly Pande ◽  
...  
Keyword(s):  
Systematic Review ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Clinical Benefit ◽  
Meta Analysis ◽  
Ductal Adenocarcinoma

P-P48 Clinical Benefit of Surveillance after Resection of Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 108 (Supplement_9) ◽  
Author(s):  
James Halle-Smith ◽  
Lewis Hall ◽  
Lois Daamen ◽  
James Hodson ◽  
Rupaly Pande ◽  
...  
Keyword(s):  
Systematic Review ◽  
Overall Survival ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Clinical Benefit ◽  
Meta Analysis ◽  
Ductal Adenocarcinoma ◽  
Surveillance Program ◽  
Routine Surveillance ◽  
Surveillance Programs ◽  
Asymptomatic Stage

Abstract Background The clinical benefit and acceptability to patients of routine surveillance after resection of pancreatic ductal adenocarcinoma (PDAC) remains unclear. Furthermore, expert guidelines around the world offer conflicting recommendations. This study is a systematic review of evidence for surveillance programs. Methods A systematic review of studies evaluating different surveillance methods was undertaken. Meta-analyses were performed for those studies reporting rates of asymptomatic recurrence, treatment of recurrence and overall survival, according to different surveillance methods. Results There were ten studies included in the literature review. Five studies were appropriate for meta-analysis (1,596 patients). If enrolled in an active surveillance program, patients were more likely to have recurrence detected at an asymptomatic stage (Pooled Rate: 49.3% vs. 19.1%, p = 0.043). In terms of clinical outcomes, patients with asymptomatic recurrence were more likely to receive treatment for recurrence (Odds Ratio 3.49; 95% CI: 1.73-7.07; p < 0.001) and had longer overall survival (Mean Difference: 9.5 months; 95% CI: 4.1-14.8; p < 0.001) than those with symptoms at time of recurrence. Conclusions From this systematic review and meta-analysis of early data it appears that routine surveillance after surgery for PDAC detects more patients at the asymptomatic stage. Data from these non-randomised trials also suggest that treatment rates and survival may be superior in patients were recurrence is detected when asymptomatic. As such, these data suggest that routine surveillance may improve patient outcomes, however an appropriately conducted trial would be required to address concerns that various sources of bias may be affecting these results.

scholarly journals Intraductal papillary mucinous carcinoma versus pancreatic ductal adenocarcinoma: A systematic review and meta-analysis

2019 ◽  
Vol 71 ◽  
pp. 91-99 ◽  
Author(s):  
Linus Aronsson ◽  
Axel Bengtsson ◽  
William Torén ◽  
Roland Andersson ◽  
Daniel Ansari
Keyword(s):  
Systematic Review ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Meta Analysis ◽  
Mucinous Carcinoma ◽  
Ductal Adenocarcinoma

scholarly journals Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis

2011 ◽  
Vol 17 (10) ◽  
pp. 3316-3331 ◽  
Author(s):  
Nigel B. Jamieson ◽  
C. Ross Carter ◽  
Colin J. McKay ◽  
Karin A. Oien
Keyword(s):  
Systematic Review ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Meta Analysis ◽  
Ductal Adenocarcinoma ◽  
Tissue Biomarkers

Does pain predict survival in patients with pancreatic ductal adenocarcinoma? A systematic review and meta-analysis

Pancreatology ◽  
2015 ◽  
Vol 15 (3) ◽  
pp. S18
Author(s):  
Stephan Schorn ◽  
Charlotte Schneider ◽  
Ihsan Ekin Demir ◽  
Helmut Friess ◽  
Güralp Onur Ceyhan
Keyword(s):  
Systematic Review ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Meta Analysis ◽  
Ductal Adenocarcinoma
Sign in / Sign up

Export Citation Format

Share Document